A firestorm erupted this week in response to the pharmaceutical company Mylan’s sharp increase in the price of its EpiPen, a life-saving treatment for severe allergic reactions. The company quickly backtracked, announcing a rebate plan. Here, three Northeastern faculty members—pharmacist Tayla Rose, healthcare finance expert Steven Pizer, and health policy researcher Gary Young—explain the clinical, economic, and policy implications of the controversy.
Over the past 10 years, the U.S. healthcare sector’s greenhouse gas emissions grew by more than 30 percent, accounting for 9.8 percent of the national total in 2013. “If the U.S. healthcare sector were itself a country, it would rank 13th in the world for greenhouse gas emissions, ahead of the entire U.K.,” states a new paper coauthored by Northeastern researcher Matthew Eckelman.